{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:38:36Z","timestamp":1765280316349},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,7]]},"DOI":"10.7759\/cureus.23906","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T10:36:25Z","timestamp":1649327785000},"source":"Crossref","is-referenced-by-count":1,"title":["Dasatinib-Induced Bilateral Pleural Effusions"],"prefix":"10.7759","author":[{"given":"Taha F","family":"Rasul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Motoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah NP","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C, et al.. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016, 91:869-74. 10.1002\/ajh.24423","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural effusion in dasatinib-treated patients With chronic myeloid leukemia in chronic phase: identification and management","volume":"17","author":"Cortes JE","year":"2017","unstructured":"Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural effusion in dasatinib-treated patients With chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk. 2017, 17:78-82. 10.1016\/j.clml.2016.09.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2020","article-title":"Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia","volume":"31","author":"Latagliata R","year":"2013","unstructured":"Latagliata R, Breccia M, Fava C, et al.. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol. 2013, 31:103-9. 10.1002\/hon.2020","journal-title":"Hematol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2012.11.006","article-title":"The Light criteria: the beginning and why they are useful 40 years later","volume":"34","author":"Light RW","year":"2013","unstructured":"Light RW. The Light criteria: the beginning and why they are useful 40 years later. Clin Chest Med. 2013, 34:21-6. 10.1016\/j.ccm.2012.11.006","journal-title":"Clin Chest Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron A","year":"2007","unstructured":"Bergeron A, R\u00e9a D, Levy V, et al.. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007, 176:814-8. 10.1164\/rccm.200705-715CR","journal-title":"Am J Respir Crit Care Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama A","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007, 25:3908-14. 10.1200\/JCO.2007.12.0329","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10018-1157","article-title":"he evaluation of serum ascites albumin gradient and portal hypertensive changes in cirrhotic patients with ascites","volume":"6","author":"Shahed FH","year":"2016","unstructured":"Shahed FH, Mamun-Al-Mahtab, Rahman S. he evaluation of serum ascites albumin gradient and portal hypertensive changes in cirrhotic patients with ascites. Euroasian J Hepatogastroenterol. 2016, 6:8-9. 10.5005\/jp-journals-10018-1157","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2237","article-title":"A man with pleural effusion and ascites","volume":"147","author":"Li A","year":"2015","unstructured":"Li A, Poon L, Khoo KL, Seet JE, Sinha AK, Lee P. A man with pleural effusion and ascites. Chest. 2015, 147:e208-14. 10.1378\/chest.14-2237","journal-title":"Chest"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2009.11928526","article-title":"Discovering the elusive underlying cause of a bilateral effusion combined with ascites","volume":"22","author":"Zhang J","year":"2009","unstructured":"Zhang J, Tingle L, Nair R, et al.. Discovering the elusive underlying cause of a bilateral effusion combined with ascites. Proc Bayl Univ Med Cent. 2009, 22:239-41. 10.1080\/08998280.2009.11928526","journal-title":"Proc Bayl Univ Med Cent"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2009.03.007","article-title":"Ascites: diagnosis and management","volume":"93","author":"Hou W","year":"2009","unstructured":"Hou W, Sanyal AJ. Ascites: diagnosis and management. Med Clin North Am. 2009, 93:801-17, vii. 10.1016\/j.mcna.2009.03.007","journal-title":"Med Clin North Am"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-6-85","article-title":"Management of malignant pleural effusion and ascites by a triple access multi perforated large diameter catheter port system","volume":"6","author":"Inan I","year":"2008","unstructured":"Inan I, De Sousa S, Myers PO, Bouclier B, Dietrich PY, Hagen ME, Morel P. Management of malignant pleural effusion and ascites by a triple access multi perforated large diameter catheter port system. World J Surg Oncol. 2008, 6:85. 10.1186\/1477-7819-6-85","journal-title":"World J Surg Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0122-3","article-title":"Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib","volume":"8","author":"Ottmann O","year":"2018","unstructured":"Ottmann O, Saglio G, Apperley JF, et al.. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer J. 2018, 8:88. 10.1038\/s41408-018-0122-3","journal-title":"Blood Cancer J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2019.03.002","article-title":"Analytical validation of a highly sensitive, multiplexed chronic myeloid leukemia monitoring system targeting BCR-ABL1 RNA","volume":"21","author":"Brown JT","year":"2019","unstructured":"Brown JT, Beldorth IJ, Laosinchai-Wolf W, et al.. Analytical validation of a highly sensitive, multiplexed chronic myeloid leukemia monitoring system targeting BCR-ABL1 RNA. J Mol Diagn. 2019, 21:718-33. 10.1016\/j.jmoldx.2019.03.002","journal-title":"J Mol Diagn"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/1817-1737.191871","article-title":"Dasatinib-induced pleural effusion: chylothorax, an option to consider","volume":"11","author":"Ferreiro L","year":"2016","unstructured":"Ferreiro L, San-Jos\u00e9 E, Su\u00e1rez-Antelo J, Vald\u00e9s L. Dasatinib-induced pleural effusion: chylothorax, an option to consider. Ann Thorac Med. 2016, 11:289-93. 10.4103\/1817-1737.191871","journal-title":"Ann Thorac Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030494","article-title":"Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily","volume":"96","author":"Krauth MT","year":"2011","unstructured":"Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schl\u00f6gl E, Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011, 96:163-6. 10.3324\/haematol.2010.030494","journal-title":"Haematologica"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i1.8914","article-title":"Dasatinib induced pleuro-pericardial effusion","volume":"91","author":"Mishra AK","year":"2020","unstructured":"Mishra AK, Sahu KK, Kaul S, Lal A. Dasatinib induced pleuro-pericardial effusion. Acta Biomed. 2020, 91:142-3. 10.23750\/abm.v91i1.8914","journal-title":"Acta Biomed"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91668-z","article-title":"Meta-analysis of value of propranolol in prevention of variceal haemorrhage","volume":"4","author":"Hayes PC","year":"1990","unstructured":"Hayes PC, Davis JM, Lewis JA, et al.. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet. 1990, 4:153-6. 10.1016\/0140-6736(90)91668-z","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/81519-dasatinib-induced-bilateral-pleural-effusions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:32Z","timestamp":1707507872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/81519-dasatinib-induced-bilateral-pleural-effusions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.23906","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}